@article{abb1f4c5552d4fcaadccee78e024a21a,
title = "Nanotechnology for pain management: Current and future therapeutic interventions",
abstract = "Pain is one of the most common medical conditions and affects more Americans than diabetes, heart disease, and cancer combined. Current pain treatments mainly rely on opioid analgesics and remain unsatisfactory. The life-threatening side effects and addictive properties of opioids demand new therapeutic approaches. Nanomedicine may be able to address these challenges as it allows for sensitive and targeted treatments without some of the burdens associated with current clinical pain therapies. This review discusses the physiology of pain, the current landscape of pain treatment, novel targets for pain treatment, and recent and ongoing efforts to effectively treat pain using nanotechnology-based approaches. We highlight advances in nanoparticle-based drug delivery to reduce side effects, gene therapy to tackle the source of pain, and nanomaterials-based scavenging to proactively mediate pain signaling.",
keywords = "CRISPR, Drug delivery, Gene therapy, Nanomedicine, Pain, ROS scavenging",
author = "Divya Bhansali and Teng, {Shavonne L.} and Lee, {Caleb S.} and Schmidt, {Brian L.} and Bunnett, {Nigel W.} and Leong, {Kam W.}",
note = "Funding Information: Divya Bhansali obtained her Bachelors of Science in Biomedical Engineering from the University of Miami. She is currently a Ph.D. student in the Department of Biomedical Engineering at Columbia University. Her research interests include investigating nanoparticles and their application in therapeutic platforms for cancer treatment, pain management, and inflammation modulation. She is a recipient the NSF Graduate Research Fellowship and Columbia University{\textquoteright}s Blavatnik Presidential Fellowship. Funding Information: Dr. Brian L. Schmidt is a surgeon and scientist. He earned his advanced degrees at the University of California, San Francisco. He is a Professor in the Departments of Oral and Maxillofacial Surgery and Neuroscience and Physiology. He directs Bluestone Center for Clinical Research at New York University as well as the NYU Oral Cancer Center. Dr. Schmidt{\textquoteright}s clinical efforts are dedicated to comprehensive surgical management of oral cancer; his scientific work explores the neurobiology of oral cancer pain. His clinical and basic science research have been funded by the NIH since 2005. Funding Information: Support by National Institutes of Health (NS102722, DE026806, DK118971, DE029951, NWB, BLS) and Department of Defense (W81XWH1810431, NWB, BLS) is acknowledged. Images were created with the assistance of Biorender.com. Publisher Copyright: {\textcopyright} 2021 Elsevier Ltd",
year = "2021",
month = aug,
doi = "10.1016/j.nantod.2021.101223",
language = "English (US)",
volume = "39",
journal = "Nano Today",
issn = "1748-0132",
publisher = "Elsevier",
}